Patents by Inventor Mark F. Pittenger

Mark F. Pittenger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20110158964
    Abstract: Disclosed is a method for producing cardiomyocytes in vivo by administering to the heart of an individual a cardiomyocyte producing amount of mesenchymal stem cells. These cells can be administered as a liquid injectible or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be genetically modified to enhance myocardial differentiation and integration. Also disclosed is a method for replacing cells ex vivo in a heart valve for implantation.
    Type: Application
    Filed: January 25, 2011
    Publication date: June 30, 2011
    Inventors: Mark F. Pittenger, Stephen L. Gordon, Alastair Morgan Mackay, Bradley J. Martin
  • Publication number: 20110142807
    Abstract: Methods of treating autoimmune diseases, allergic responses, cancer, or inflammatory diseases in an animal, promoting would healing, and promoting angiogenesis in an organ or tissue of an animal by administering to the animal mesenchymal stem cells in an effective amount.
    Type: Application
    Filed: December 21, 2010
    Publication date: June 16, 2011
    Inventors: Mark F. Pittenger, Sudeepta Aggarwal
  • Patent number: 7892829
    Abstract: Disclosed is a method for producing cardiomyocytes in vivo by administering to the heart of an individual a cardiomyocyte producing amount of mesenchymal stem cells. These cells can be administered as a liquid injectable or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be genetically modified to enhance myocardial differentiation and integration. Also disclosed is a method for replacing cells ex vivo in a heart valve for implantation.
    Type: Grant
    Filed: March 2, 2009
    Date of Patent: February 22, 2011
    Assignee: Osiris Therapeutics, Inc.
    Inventors: Mark F. Pittenger, Stephen L. Gordon, Alastair Morgan Mackay, Bradley J. Martin
  • Publication number: 20110027238
    Abstract: Methods of treating autoimmune diseases, allergic responses, cancer, or inflammatory diseases in an animal, promoting would healing, repairing epithelial damage and promoting angiogenesis in an organ or tissue of an animal by administering to the animal mesenchymal stem cells in an effective amount.
    Type: Application
    Filed: October 20, 2010
    Publication date: February 3, 2011
    Inventors: Sudeepta Aggarwal, Mark F. Pittenger, Timothy Varney
  • Publication number: 20100330048
    Abstract: Methods of treating autoimmune diseases, allergic responses, cancer, inflammatory diseases, or fibrosis in an animal, promoting would healing, repairing epithelial damage and promoting angiogenesis in an organ or tissue of an animal by administering to the animal mesenchymal stem cells in an effective amount.
    Type: Application
    Filed: August 25, 2010
    Publication date: December 30, 2010
    Inventors: Sudeepta Aggarwal, Mark F. Pittenger, Timothy Varney, Alla Danilkovitch
  • Publication number: 20100172885
    Abstract: Disclosed are cell preparations comprising multipotent adult stem cells and methods for using multipotent adult stem cells to treat autoimmune diseases, treat allergic responses, treat cancer, treat inflammatory diseases, treat fibrotic disorders, reduce inflammation and/or fibrosis, promote would healing, repair epithelial damage, and/or promote angiogenesis.
    Type: Application
    Filed: March 19, 2010
    Publication date: July 8, 2010
    Applicant: OSIRIS THERAPEUTICS, INC.
    Inventors: Mark F. Pittenger, Sudeepta Aggarwal
  • Publication number: 20100172884
    Abstract: Disclosed are compositions and methods for repairing and/or regenerating cardiac tissue by administering adult bone marrow-derived stem cells to an individual. These cells can be administered as a liquid injectible or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be genetically modified to enhance myocardial differentiation and integration. Also disclosed is a method for replacing cells ex vivo in a heart valve for implantation.
    Type: Application
    Filed: March 17, 2010
    Publication date: July 8, 2010
    Inventors: Mark F. Pittenger, Stephen L. Gordon, Alastair Morgan Mackay
  • Publication number: 20090220464
    Abstract: Methods of treating autoimmune diseases, allergic responses, cancer, inflammatory diseases, or fibrosis in an animal, promoting would healing, repairing epithelial damage and promoting angiogenesis in an organ or tissue of an animal by administering to the animal mesenchymal stem cells in an effective amount.
    Type: Application
    Filed: March 21, 2008
    Publication date: September 3, 2009
    Inventors: Sudeepta Aggarwal, Mark F. Pittenger, Timothy Varney, Alla Danilkovitch
  • Publication number: 20090214493
    Abstract: Disclosed is a method for producing cardiomyocytes in vivo by administering to the heart of an individual a cardiomyocyte producing amount of mesenchymal stem cells. These cells can be administered as a liquid injectable or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be genetically modified to enhance myocardial differentiation and integration. Also disclosed is a method for replacing cells ex vivo in a heart valve for implantation.
    Type: Application
    Filed: March 2, 2009
    Publication date: August 27, 2009
    Applicant: Osiris Therapeutics, Inc.
    Inventors: Mark F. Pittenger, Stephen L. Gordon, Alastair Morgan Mackay, Bradley J. Martin
  • Publication number: 20090208463
    Abstract: Methods of treating autoimmune diseases, allergic responses, cancer, or inflammatory diseases in an animal, promoting wound healing, repairing epithelial damage and promoting angiogenesis in an organ or tissue of an animal by administering to the animal mesenchymal stem cells in an effective amount.
    Type: Application
    Filed: September 26, 2007
    Publication date: August 20, 2009
    Inventors: Mark F. Pittenger, Timothy Varney, Sudeepta Aggarwal
  • Publication number: 20090180997
    Abstract: Methods of treating autoimmune diseases, allergic responses, cancer, or inflammatory diseases in an animal, promoting would healing, and promoting anglogenesis in an organ or tissue of an animal by administering to the animal mesenchymal stem cells in an effective amount.
    Type: Application
    Filed: November 25, 2008
    Publication date: July 16, 2009
    Inventors: Mark F. Pittenger, Sudeepta Aggarwal
  • Patent number: 7514074
    Abstract: Disclosed is a method for producing cardiomyocytes in vivo by administering to the heart of an individual a cardiomyocyte producing amount of mesenchymal stem cells. These cells can be administered as a liquid injectible or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be genetically modified to enhance myocardial differentiation and integration. Also disclosed is a method for replacing cells ex vivo in a heart valve for implantation.
    Type: Grant
    Filed: October 21, 2003
    Date of Patent: April 7, 2009
    Assignee: Osiris Therapeutics, Inc.
    Inventors: Mark F. Pittenger, Stephen L. Gordon, Alastair Morgan Mackay, Bradley J. Martin
  • Publication number: 20080213227
    Abstract: Methods of treating autoimmune diseases, allergic responses, cancer, or inflammatory diseases in an animal, promoting would healing, repairing epithelial damage and promoting angiogenesis in an organ or tissue of an animal by administering to the animal mesenchymal stem cells in an effective amount.
    Type: Application
    Filed: October 2, 2006
    Publication date: September 4, 2008
    Inventors: Sudeepta Aggarwal, Mark F. Pittenger, Timothy Varney
  • Patent number: 6709864
    Abstract: A composition which comprises human mesenchymal stem cells which have the potential to differentiate into cells of more than one connective tissue type and a composition which induces cells from the mesenchymal stem cell population to differentiate into the adipogenic lineage, and a process for inducing such differentiation. The composition for inducing such differentiation comprises a glucocorticoid, a compound which stimulates cAMP production or inhibits cAMP degradation (such as a phosphodiesterase inhibitor), and/or a compound which upregulates peroxisome proliferator activated receptor &ggr; (PPAR &ggr;) expression and/or increases its binding affinity to its DNA binding site. The process can further include isolating the adipocytes from remaining hMSCs.
    Type: Grant
    Filed: March 28, 2000
    Date of Patent: March 23, 2004
    Assignee: Osiris Therapeutics, Inc.
    Inventors: Mark F. Pittenger, Stephen C. Beck
  • Publication number: 20030103951
    Abstract: Disclosed is a method for producing cardiomyocytes in vivo by administering to the heart of an individual a cardiomyocyte producing amount of mesenchymal stem cells. These cells can be administered as a liquid injectible or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be genetically modified to enhance myocardial differentiation and integration. Also disclosed is a method for replacing cells ex vivo in a heart valve for implantation.
    Type: Application
    Filed: October 22, 2002
    Publication date: June 5, 2003
    Applicant: Osiris Therapeutics, Inc.
    Inventors: Mark F. Pittenger, Stephen L. Gordon, Alastair Morgan Mackay, Bradley J. Martin
  • Publication number: 20030026786
    Abstract: Disclosed are a composition of chemically defined components having elevated levels of simple sugars which support the enhanced in vitro chondrogenesis of mesenchymal progenitor cells, a method for in vitro chondrogenic induction of such progenitor cells and a method of forming human chondrocytes in vitro from such progenitor cells.
    Type: Application
    Filed: June 4, 1999
    Publication date: February 6, 2003
    Inventors: MARK F. PITTENGER, ALASTAIR M. MACKAY, J. MARY MURPHY, FRANCIS P. BARRY
  • Patent number: 6387369
    Abstract: Disclosed is a method for producing cardiomyocytes in vivo by administering to the heart of an individual a cardiomyocyte producing amount of mesenchymal stem cells. These cells can be administered as a liquid injectible or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be genetically modified to enhance myocardial differentiation and integration. Also disclosed is a method for replacing cells ex vivo in a heart valve for implantation.
    Type: Grant
    Filed: March 27, 2000
    Date of Patent: May 14, 2002
    Assignee: Osiris Therapeutics, Inc.
    Inventors: Mark F. Pittenger, Stephen L. Gordon, Alastair Morgan Mackay
  • Patent number: 6322784
    Abstract: A composition which comprises human mesenchymal stem cells which have the potential to differentiate into cells of more than one connective tissue type and a composition which induces cells from the mesenchymal stem cell population to differentiate into the adipogenic lineage, and a process for inducing such differentiation. The composition for inducing such differentiation comprises a glucocorticoid, a compound which stimulates cAMP production or inhibits cAMP degradation (such as a phosphodiesterase inhibitor), and/or a compound which upregulates peroxisome proliferator activated receptor &ggr; (PPAR &ggr;) expression and/or increases its binding affinity to its DNA binding site. The process can further include isolating the adipocytes from remaining hMSCs.
    Type: Grant
    Filed: October 26, 1998
    Date of Patent: November 27, 2001
    Assignee: Osiris Therapeutics, Inc.
    Inventors: Mark F. Pittenger, Stephen C. Beck
  • Patent number: 6030836
    Abstract: The present invention is directed to human mesenchymal stem cells isolated from a tissue specimen, such as marrow cells, and to the method of co-culturing isolated mesenchymal stem cells and/or mesenchymal stem cell-derived adipocytes with hematopoietic progenitor cells such that the hematopoietic stem cells retain their phenotype.
    Type: Grant
    Filed: June 8, 1999
    Date of Patent: February 29, 2000
    Assignee: Osiris Therapeutics, Inc.
    Inventors: Mark A. Thiede, Mark F. Pittenger, Gabriel Mbalaviele
  • Patent number: 5827740
    Abstract: A composition which comprises human mesenchymal stem cells which have the potential to differentiate into cells of more than one connective tissue type and a composition which induces cells from the mesenchymal stem cell population to differentiate into the adipogenic lineage, and a process for inducing such differentiation. The composition for inducing such differentiation comprises a glucocorticoid and a compound which stimulates cAMP production or inhibits cAMP degradation (such as a phosphodiesterase inhibitor). The process can further include isolating the adipocytes from remaining hMSCs.
    Type: Grant
    Filed: July 30, 1996
    Date of Patent: October 27, 1998
    Assignee: Osiris Therapeutics, Inc.
    Inventor: Mark F. Pittenger